Overview
Eosinophilia-myalgia syndrome (EMS) is characterized by marked eosinophilia and widespread myalgia, often linked to the consumption of L-tryptophan-containing products 2. It can present with additional complications such as interstitial lung disease 1.Diagnosis
Key Criteria: Eosinophil count >1000 cells/μL, intense eosinophilia, and debilitating generalized myalgia without infectious or neoplastic causes 2.
Recommended Tests: Consider evaluation of interstitial lung disease with diffusing capacity, gallium scans, bronchoalveolar lavage, and possibly lung biopsy in suspected cases 1.Management
First-Line: Discontinue L-tryptophan-containing products immediately upon suspicion of EMS 2.
Adjunctive Treatments: Specific drug classes and doses are not detailed in the provided abstracts; supportive care including pain management and symptomatic treatment are implied 2.Special Populations
No Specific Guidance: The abstracts do not provide specific management recommendations for pregnancy, pediatrics, elderly, or patients with comorbidities 12.Key Recommendations
Discontinue L-tryptophan exposure in suspected cases of EMS to prevent further complications (Evidence: Strong 2).
Comprehensive evaluation of lung function is recommended in patients with suspected EMS, including tests like diffusing capacity and bronchoalveolar lavage (Evidence: Moderate 1).
Supportive care measures should be implemented to manage symptoms such as myalgia and other manifestations (Evidence: Expert opinion 2).References
1 Chauhan D, Mengel CE. Eosinophilia-myalgia syndrome and fasciitis with an active alveolitis. Kansas medicine : the journal of the Kansas Medical Society 1993. link
2 Wong CB, Love J, Pon E, Scottolini AG, Manoukian AA. L-tryptophan-related eosinophilia-myalgia syndrome: a case report. Hawaii medical journal 1990. link